Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris

Lauren Bonomo, Jacob O. Levitt

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Refractory pityriasis rubra pilaris (PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis, most commonly tumor necrosis factor (TNF) α antagonists and ustekinumab; however, the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab.

Original languageEnglish
Pages (from-to)367-369
Number of pages3
JournalCutis
Volume101
Issue number5
StatePublished - May 2018

Fingerprint

Dive into the research topics of 'Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris'. Together they form a unique fingerprint.

Cite this